4-AcO-MET

4-AcO-MET is not expressly listed in the federal controlled-substance schedules current through August 27, 2026, and no later DEA scheduling publication through August 28 was found. FDA identifies the substance as 4-acetoxyethylmethyltryptamine (also 4-acetoxy-MET and metacetin; CAS 1445751-40-5; formula C15H20N2O2). Schedule I at 21 CFR § 1308.11(d) lists Psilocyn, and DEA/FDA identify Psilocyn as psilocin (4-hydroxy-N,N-dimethyltryptamine; formula C12H16N2O). That confirms psilocin is a Schedule I comparator, but it does not establish that 4-AcO-MET meets 21 U.S.C. § 802(32)'s substantial-similarity criteria. No inspected DEA, Federal Register, or other primary federal source makes a substance-specific analogue determination for 4-AcO-MET. Under 21 U.S.C. § 813, a substance that first qualifies as a controlled substance analogue is treated as Schedule I to the extent intended for human consumption; intent alone does not establish analogue identity. This designation is limited to direct federal scheduling, does not classify 4-AcO-MET as analog_covered, and does not address state law or a transaction-specific prosecution.

4-AcO-MET is controlled throughout the United Kingdom as a Class A drug through the Misuse of Drugs Act 1971 structural generic and ester provisions, rather than by an individual 4-AcO-MET name entry. The Home Office has expressly identified 4-Acetoxy-N-methyl-N-ethyltryptamine (a verified synonym of 4-AcO-MET) and 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET) as Class A drugs under the generic tryptamine clause. The official chemical records show that 4-HO-MET is a ring-hydroxy tryptamine with methyl and ethyl groups on its side-chain nitrogen and that 4-AcO-MET is its 4-acetate ester. MDA Schedule 2 Part I paragraph 1(b)(i) captures the N-alkyl-substituted ring-hydroxy parent and paragraph 3 captures its ester. The corresponding generic and ester provisions place it in MDR Schedule 1 in England, Wales and Scotland and, through operative parallel amendments, in Schedule 1 in Northern Ireland. Home Office guidance describes the expanded-generic compounds as designated drugs without recognized medicinal or legitimate use outside licensed research. Unauthorized possession is unlawful under MDA section 5, subject to regulations and statutory defences. Canonical status is analog_covered because coverage is structural/class-based, notwithstanding its Class A legal classification.